Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Copanlisib to Deepen Response in CLL Patients on Ibrutinib or Acalabrutinib in the Relapsed/Refractory Setting

NCT04685915 is registered in ClinicalTrials.gov with Inhye Ahn as lead sponsor.

NCT NCT04685915
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04685915 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Copanlisib to Deepen Response in CLL Patients on Ibrutinib or Acalabrutinib in the Relapsed/Refractory Setting
Lead sponsor
Inhye Ahn
Phase
Phase 2
Overall status
Withdrawn
Start date
February 18, 2021
Completion date
March 1, 2028
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

chronic lymphocytic leukemia (cll)